Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers

Gynecol Oncol. 2021 Feb;160(2):625-632. doi: 10.1016/j.ygyno.2020.10.026. Epub 2020 Nov 4.

Abstract

Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials.

Keywords: Gynecologic cancers; Lymphedema; Oncologic surgical treatment; Patient reported outcomes; Quantitative measurements.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Anthropometry / methods*
  • Chemotherapy, Adjuvant / adverse effects
  • Dielectric Spectroscopy / methods
  • Dielectric Spectroscopy / standards
  • Female
  • Genital Neoplasms, Female / complications
  • Genital Neoplasms, Female / therapy*
  • Gynecologic Surgical Procedures / adverse effects
  • Humans
  • Lower Extremity / pathology*
  • Lymph Node Excision / adverse effects
  • Lymphedema / diagnosis*
  • Lymphedema / etiology
  • Lymphedema / pathology
  • Lymphedema / therapy
  • Organ Size
  • Patient Reported Outcome Measures*
  • Radiotherapy, Adjuvant / adverse effects
  • Risk Factors
  • Sentinel Lymph Node Biopsy / adverse effects
  • Treatment Outcome